Prognostic Value of HHLA2 in Patients with Solid Tumors: A Meta-Analysis.
Agnieszka KulaMiriam DawidowiczSylwia MielcarskaElżbieta ŚwiętochowskaDariusz WaniczekPublished in: International journal of molecular sciences (2024)
HHLA2 is a checkpoint from the B7 family that can play a co-stimulatory or co-inhibitory role in cancer, depending on the binding receptor. The aim of this meta-analysis was to assess the relationship between HHLA2 levels and its impact on the prognosis of patients with solid cancers. The study used data from PubMed, Embase, Web of Science (WOS), Cochrane and SCOPUS databases. The R studio software was used for the data analysis. The study assessed overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) by pooling appropriate hazard ratios (HR). Eighteen studies (2880 patients' data) were included. High expression of HHLA2 was associated with worse OS (HR = 1.58, 95% CI: 1.23-2.03), shorter RFS (HR = 1.95, 95% CI: 1.38-2.77) and worse DFS (HR = 1.45, 95% CI: 1.01-2.09) in patients with solid cancers. The current study suggests that high expression of HHLA2 is associated with poorer prognosis in patients with solid cancers.
Keyphrases
- free survival
- data analysis
- systematic review
- poor prognosis
- end stage renal disease
- randomized controlled trial
- binding protein
- dna damage
- public health
- chronic kidney disease
- ejection fraction
- big data
- oxidative stress
- case control
- transcription factor
- cell cycle
- artificial intelligence
- dna binding
- childhood cancer